Emergent BioSolutions (EBS) Short-term Investments (2010 - 2026)

Emergent BioSolutions' Short-term Investments history runs 11 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• On a quarterly basis, Short-term Investments fell 67.57% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $1.2 million, a 67.57% decrease from a year earlier, with the FY2025 full-year figure at $3.7 million, down 39.34% from the prior year.
• Short-term Investments retreated to $1.2 million in Q1 2026 per EBS's latest filing, from $3.7 million in the prior quarter.
• Across five years, Short-term Investments topped out at $6.5 million in Q3 2024 and bottomed at $100000.0 in Q3 2022.
• The 4-year median for Short-term Investments is $2.5 million (2024), against an average of $2.6 million.
• Across the five-year window, Short-term Investments surged 640.0% in 2025 and slumped 67.57% in 2026, its largest moves.
• Year by year, Short-term Investments stood at $100000.0 in 2022, then soared by 6000.0% to $6.1 million in 2024, then sank by 39.34% to $3.7 million in 2025, then slumped by 67.57% to $1.2 million in 2026.
• Per Business Quant, the three latest EBS Short-term Investments figures stand at $1.2 million (Q1 2026), $3.7 million (Q4 2025), and $3.7 million (Q3 2025).